FGF2 and neoplasm: A clinical analysis showed that patients with the FGF2 rs308447 TT genotype had shorter overall survival than patients with the CC or CT genotype (p=0.016) and that FGF2 rs308379 A allele carriers had shorter overall survival than patients with the TT genotype (p=0.020), suggesting that the FGF2 rs308379 A allele and advanced tumor stage were independent prognostic factors for overall survival in patients with HCC [14].